MCT’s collaboration with Onxeo on HCC Phase III study in Middle East

/ News /

Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag

Related Posts

MCT new Office in Lebanon

News /

MCT inaugurates in April 15 it new office in Lebanon in Beirut. New office will remain within Berytech Technology and Health but will provide more…